Hinshaw MA, Rubin A. Inflammatory diseases of the nail unit. Semin Cutan Med Surg. 2015;34(2):109–16. https://doi.org/10.12788/j.sder.2015.0132.

Article  PubMed  Google Scholar 

Reich A, Szepietowski JC. Health-related quality of life in patients with nail disorders. Am J Clin Dermatol. 2011;12(5):313–20. https://doi.org/10.2165/11592120-000000000-00000.

Article  PubMed  Google Scholar 

Stewart CR, Algu L, Kamran R, Leveille CF, Abid K, Rae C, et al. The impact of nail psoriasis and treatment on quality of life: a systematic review. Skin Append Disord. 2021;7(2):83–9. https://doi.org/10.1159/000512688.

Article  Google Scholar 

Belyayeva E, Gregoriou S, Chalikias J, Kontochristopoulos G, Koumantaki E, Makris M, et al. The impact of nail disorders on quality of life. Eur J Dermatol. 2013;23(3):366–71. https://doi.org/10.1684/ejd.2013.2048.

Article  PubMed  Google Scholar 

Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis, the unknown burden of disease. J Eur Acad Dermatol Venereol. 2014;28(12):1690–5. https://doi.org/10.1111/jdv.12368.

Article  CAS  PubMed  Google Scholar 

Iorizzo M, Vollono L, Richert B. Diagnosis and management of malignant epithelial nail unit tumors. Diagnostics (Basel). 2024;14(21):2379. https://doi.org/10.3390/diagnostics14212379.

Article  PubMed  PubMed Central  Google Scholar 

Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–44. https://doi.org/10.1016/j.jaad.2016.12.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017;47(7):1096–107. https://doi.org/10.1002/eji.201646680.

Article  CAS  PubMed  Google Scholar 

Huang MY, Armstrong AW. Janus-kinase inhibitors in dermatology: a review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease. Indian J Dermatol Venereol Leprol. 2023;90(1):30–40. https://doi.org/10.25259/ijdvl_15_2023.

Fleischmann R. Recent issues in JAK inhibitor safety: perspective for the clinician. Expert Rev Clin Immunol. 2022;18(3):295–307. https://doi.org/10.1080/1744666x.2022.2039122.

Article  CAS  PubMed  Google Scholar 

Jalles C, Lepelley M, Mouret S, Charles J, Leccia MT, Trabelsi S. Skin cancers under Janus kinase inhibitors: a World Health Organization drug safety database analysis. Therapie. 2022;77(6):649–56. https://doi.org/10.1016/j.therap.2022.04.005.

Article  PubMed  Google Scholar 

Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13(3):729–49. https://doi.org/10.1007/s13555-023-00892-5.

Article  PubMed  PubMed Central  Google Scholar 

Ingrassia JP, Maqsood MH, Gelfand JM, Weber BN, Bangalore S, Lo Sicco KI, et al. Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis. JAMA Dermatol. 2024;160(1):28–36. https://doi.org/10.1001/jamadermatol.2023.4090.

Article  PubMed  Google Scholar 

Talasila S, Lee E, Teichner EM, Siegfried EC, Jackson Cullison SR. Analysis of publicly available adverse events reported for pediatric patients treated with Janus kinase inhibitors. Pediatr Dermatol. 2024;41(6):1040–6. https://doi.org/10.1111/pde.15721.

Article  PubMed  Google Scholar 

Ireland PA, Verheyden M, Jansson N, Sebaratnam D, Sullivan J. Infection risk with JAK inhibitors in dermatoses: a meta-analysis. Int J Dermatol. 2025;64(1):24–36. https://doi.org/10.1111/ijd.17501.

Article  CAS  PubMed  Google Scholar 

Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, Gadina M, Heinz LX, et al. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis. 2024;83(2):139–60. https://doi.org/10.1136/ard-2023-223850.

Article  CAS  PubMed  Google Scholar 

Virtanen A, Spinelli FR, Telliez JB, O’Shea JJ, Silvennoinen O, Gadina M. JAK inhibitor selectivity: new opportunities, better drugs? Nat Rev Rheumatol. 2024;20(10):649–65. https://doi.org/10.1038/s41584-024-01153-1.

Article  CAS  PubMed  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https://doi.org/10.1136/bmj.l4898.

Article  PubMed  Google Scholar 

Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127–33. https://doi.org/10.11124/jbisrir-d-19-00099.

Article  PubMed  Google Scholar 

Barker TH, Habibi N, Aromataris E, Stone JC, Leonardi-Bee J, Sears K, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies. JBI Evid Synth. 2024;22(3):378–88. https://doi.org/10.11124/jbies-23-00268.

Article  PubMed  Google Scholar 

Rózsa P, Degovics D, Baltás E, Gyulai R, Kemény L. Successful treatment of alopecia areata-associated trachyonychia with baricitinib. Int J Dermatol. 2024;63(8):1089–90. https://doi.org/10.1111/ijd.17137.

Article  CAS  PubMed  Google Scholar 

Wittmer A, De Jong K, Bolish L, Finklea L. Therapeutic response of alopecia areata-associated nail changes to baricitinib. Case Rep Dermatol Med. 2024;2024:8879884. https://doi.org/10.1155/2024/8879884.

Article  PubMed  PubMed Central  Google Scholar 

Dhayalan A, King BA. Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA Dermatol. 2016;152(4):492–3. https://doi.org/10.1001/jamadermatol.2015.3772.

Article  PubMed  Google Scholar 

Jaller JA, Jaller JJ, Jaller AM, Jaller-Char JJ, Ferreira SB, Ferreira R, et al. Recovery of nail dystrophy potential new therapeutic indication of tofacitinib. Clin Rheumatol. 2017;36(4):971–3. https://doi.org/10.1007/s10067-017-3574-0.

Article  PubMed  Google Scholar 

Lee JS, Huh C-H, Kwon O, Yoon H-S, Cho S, Park H-S. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib. J Dermatol Treat. 2018;29(8):819–22. https://doi.org/10.1080/09546634.2018.1466024.

Article  CAS  Google Scholar 

Dube V. Recovery of alopecia universalis with associated nail dystrophy treated with tofacitinib: a 6-year-old child’s case report. Int J Trichol. 2021;13(6):32–3. https://doi.org/10.4103/ijt.ijt_91_21.

Article  Google Scholar 

Asilian A, Mohammadian P, Shahmoradi Z. Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran. J Cosmet Dermatol. 2024;23(3):886–90. https://doi.org/10.1111/jocd.16049.

Article  PubMed  Google Scholar 

He J, Yang Y. Janus kinase 1 inhibitor abrocitinib for isolated nail lichen planus: a case report and literature review. J Dermatol Treat. 2024;35(1):2434094. https://doi.org/10.1080/09546634.2024.2434094.

Article  CAS  Google Scholar 

Chim I, Sinclair R. Effective treatment of nail lichen planus with the JAK inhibitor baricitinib. Austral J Dermatol. 2023;64(S1):49–53. https://doi.org/10.1111/ajd.14043.

Article  Google Scholar 

He J, Weng T, Zhu W, Yang Y, Li C. Alleviation of isolated nail lichen planus by the JAK1/2 inhibitor baricitinib: a case report. J Dermatol Treat. 2023;34(1):2274816. https://doi.org/10.1080/09546634.2023.2274816.

Article  CAS  Google Scholar 

Pünchera J, Laffitte E. Treatment of severe nail lichen planus with baricitinib. JAMA Dermatol. 2022;158(1):107–8. https://doi.org/10.1001/jamadermatol.2021.5082.

Article  PubMed  Google Scholar 

Iorizzo M, Haneke E. Tofacitinib as treatment for nail lichen planus associated with alopecia universalis. JAMA Dermatol. 2021;157(3):352–3.